Recent Progress of Functionalized PSMA in Radionuclide Targeted Therapy for Prostate Cancer

Recent Progress of Functionalized PSMA in Radionuclide Targeted Therapy for Prostate Cancer

Prostate cancer (PCa) is the most common malignant tumor in the male reproductive system. Prostate specific membrane antigen (PSMA) is an effective target for the diagnosis and treatment of prostate cancer. The anti-PSMA small molecule/polypeptide/monoclonal antibody labeled with the therapeutic nuc...

Full description

Bibliographic Details
Main Authors:	REN Ya'nan, LIU Teli, LI Dapeng, LI Hui, DING Jin, ZHU Hua, YANG Zhi
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2020-12-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	prostate cancer prostate specific membrane antigen radioligand therapy (rlt) functional modification in vivo metabolism clinical translation
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0353.htm

Similar Items

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ai, S., et al.
Published: (2022)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
by: Konstantin Egon Seitzer, et al.
Published: (2021-07-01)

PSMA Theranostics: Current Landscape and Future Outlook
by: Hanbo Zhang, et al.
Published: (2021-08-01)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
by: Eline A.M. Ruigrok, et al.
Published: (2019-10-01)

Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer
by: LIU Teli, et al.
Published: (2019-11-01)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
by: Majid Assadi, et al.
Published: (2020-01-01)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
by: Judith Stangl-Kremser, et al.
Published: (2021-08-01)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
by: Mohamed El Fakiri, et al.
Published: (2021-08-01)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
by: Wallace Jones, et al.
Published: (2020-05-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
by: Ashwin Singh Parihar, et al.
Published: (2021-01-01)

Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
by: Sillerud LO
Published: (2016-01-01)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
by: Philipp E. Hartrampf, et al.
Published: (2021-08-01)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
by: Veronika Barbara Felber, et al.
Published: (2021-02-01)

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway
by: Hailong Zhang, et al.
Published: (2016-05-01)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Asta Juzeniene, et al.
Published: (2021-02-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA
by: Yue-hong ZHANG, et al.
Published: (2010-12-01)

Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
by: Joshi, Jay
Published: (2020)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
by: Marie Christine Hupe, et al.
Published: (2018-12-01)

Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization
by: Zora Novakova, et al.
Published: (2020-09-01)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
by: Stephen McGeorge, et al.
Published: (2021-09-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
by: Katharina Lückerath, et al.
Published: (2018-10-01)

Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis
by: Christian H. Pfob, et al.
Published: (2018-02-01)

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
by: Spencer T. Lake, et al.
Published: (2017-09-01)

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
by: Yutong Xing, et al.
Published: (2021-05-01)

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer
by: Scott T Tagawa, et al.
Published: (2013-08-01)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
by: Zool Hilmi Awang, et al.
Published: (2018-05-01)

Synthesis and Evaluation of <sup>99m</sup>Tc-Tricabonyl Labeled Isonitrile Conjugates for Prostate-Specific Membrane Antigen (PSMA) Image
by: Nadeem Ahmed Lodhi, et al.
Published: (2020-01-01)

Application of 68Ga-PSMA-617 Molecular Probe for Micro-PET Imaging of Gliomas Model
by: HAN Xuedi, et al.
Published: (2018-07-01)

Modern directions of radionuclide diagnosis in patients with prostate cancer
by: P.O. Korol, et al.
Published: (2018-04-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Caliebe, A., et al.
Published: (2022)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
by: Wajahat Khatri, et al.
Published: (2021-04-01)

Clinical Utility of 18F-PSMA-1007 Positron Emission Tomography/Magnetic Resonance Imaging in Prostate Cancer: A Single-Center Experience
by: Ao Liu, et al.
Published: (2021-02-01)

Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT
by: Fadi Khreish, et al.
Published: (2021-08-01)

The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis
by: Rang Wang, et al.
Published: (2021-06-01)